Assessment of recurrent mesenteric ischemia after stenting with a pressure wire

Margiotta, Alyssa L.; Gray, Bruce H.

doi:10.1177/1358863x14524852

Cited by 3 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the above-described ELISA approaches, each polyclonal anti-sera sample diluted 1:250 in PBS and mAb as confluent supernatants diluted 1:3 in PBS were used as the primary antibody against peptide 1, peptide 2, or rRBD. An irrelevant mAb was used as an assay control [ 21 ]. After development, the optical density of each well was recorded at 405 nm to compare the reactivity of each mAb with each antigen.…”

Section: Methodsmentioning

confidence: 99%

Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment

Patterson,

Dubansky,

Dubansky

et al. 2023

Viruses

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is an ongoing threat to global public health. To this end, intense efforts are underway to develop reagents to aid in diagnostics, enhance preventative measures, and provide therapeutics for managing COVID-19. The recent emergence of SARS-CoV-2 Omicron variants with enhanced transmissibility, altered antigenicity, and significant escape of existing monoclonal antibodies and vaccines underlines the importance of the continued development of such agents. The SARS-CoV-2 spike protein and its receptor binding domain (RBD) are critical to viral attachment and host cell entry and are primary targets for antibodies elicited from both vaccination and natural infection. In this study, mice were immunized with two synthetic peptides (Pep 1 and Pep 2) within the RBD of the original Wuhan SARS-CoV-2, as well as the whole RBD as a recombinant protein (rRBD). Hybridomas were generated, and a panel of three monoclonal antibodies, mAb CU-P1-1 against Pep 1, mAb CU-P2-20 against Pep 2, and mAb CU-28-24 against rRBD, was generated and further characterized. These mAbs were shown by ELISA to be specific for each immunogen/antigen. Monoclonal antibody CU-P1-1 has limited applicability other than in ELISA approaches and basic immunoblotting. Monoclonal antibody CU-P2-20 is shown to be favorable for ELISA, immunoblotting, and immunohistochemistry (IHC), however, not live virus neutralization. In contrast, mAb CU-28-24 is most effective at live virus neutralization as well as ELISA and IHC. Moreover, mAb CU-28-24 is active against rRBD proteins from Omicron variants BA.2 and BA.4.5 as determined by ELISA, suggesting this mAb may neutralize live virus of these variants. Each of the immunoglobulin genes has been sequenced using Next Generation Sequencing, which allows the expression of respective recombinant proteins, thereby eliminating the need for long-term hybridoma maintenance. The synthetic peptides and hybridomas/mAbs and quantitative antigen-binding data are under the intellectual property management of the Clemson University Research Foundation, and the three CDRs have been submitted as an invention disclosure for further patenting and commercialization.

show abstract

Section: Methodsmentioning

confidence: 99%

Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment

Patterson,

Dubansky,

Dubansky

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Using the above-described ELISA approaches, each polyclonal anti-sera sample diluted 1:250 in PBS and mAb as confluent supernatants diluted 1:3 in PBS were used as primary antibody against peptide 1, peptide 2, or rRBD. An irrelevant mAb was used as an assay control [21]. After development, the optical density of each well was recorded at 405 nm to compare the reactivity of each mAb with each antigen.…”

Section: Methodsmentioning

confidence: 99%

“…An irrelevant mAb was used as an assay control [21]. After development, the optical density of each well was recorded at 405 nm to compare the reactivity of each mAb with each antigen.…”

Section: Screening Mabs For Specificitymentioning

confidence: 99%

Generation and characterization of a multi-functional panel of monoclonal antibodies for SARS-CoV-2 research and treatment

Patterson,

Dubansky,

Dubansky

et al. 2023

Preprint

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID19) pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is an ongoing threat to global public health. To this end, intense efforts are underway to develop reagents to aid in diagnostics, enhance preventative measures, and provide therapeutics for managing COVID-19. The recent emergence of SARS-CoV-2 Omicron variants with enhanced transmissibility, altered antigenicity, and significant escape of existing monoclonal antibodies and vaccines underlines the importance of the continued development of such agents. The SARS-CoV-2 spike protein and its receptor binding domain (RBD) are critical to viral attachment and host cell entry and are primary targets for antibodies elicited from both vaccination and natural infection. In this study, mice were immunized with two synthetic peptides (Pep 1 and Pep 2) within the RBD of the original Wuhan SARS-CoV-2, as well as the whole RBD as a recombinant protein (rRBD). Hybridomas were generated and a panel of three monoclonal antibodies, mAb CU-P1-1 against Pep 1, mAb CU-P2-20 against Pep 2, and mAb CU-28-24 against rRBD, were generated and further characterized. These mAbs were shown by ELISA to be specific for each immunogen/antigen. Monoclonal antibody CU-P1-1 has limited applicability other than in ELISA approaches and basic immunoblotting. Monoclonal antibody CU-P2-20 is shown to be favorable for ELISA, immunoblotting, and immunohistochemistry (IHC), however, not live virus neutralization. In contrast, mAb CU-28-24 is most effective at live virus neutralization as well as ELISA and IHC. Moreover, mAb CU-28-24 was active against rRBD proteins from Omicron variants B.2 and B.4/B5 as determined by ELISA, suggesting this mAb may neutralize live virus of these variants. Each of the immunoglobulin genes has been sequenced using Next Generation Sequencing, which allows the expression of respective recombinant proteins, thereby eliminating the need for long-term hybridoma maintenance. The synthetic peptide sequences, hybridomas, and related mAbs are now protected by Intellectual Property agreements with the Clemson University Research Foundation and are Patent Pending based on their unique amino acids within the complementary determining regions (CDRs).

show abstract

“…Intraluminal pressure measurements can be made across a stenosis at the time of arteriography if there is a question regarding the hemodynamic significance of the lesion. 77 It is worth emphasizing that the other less invasive imaging studies (ie, DUS examination, CTA, MRA) cannot provide any functional or hemodynamic data in terms of pressure gradients. Concerns have been raised about the impact of the catheter itself and its contribution to the gradient.…”

Section: Detailed Justificationmentioning

confidence: 99%

“…A catheter-based arteriogram with the measurement of intraluminal pressures may occasionally be helpful in equivocal cases to determine the hemodynamic significance of a recurrent stenosis. 77 The management of patients with a recurrent stenosis and recurrent symptoms consistent with CMI is similar to the management of a symptomatic de novo lesion. Patients should undergo a CTA to facilitate the intervention, if not already performed.…”

Section: Detailed Justificationmentioning

confidence: 99%

Chronic mesenteric ischemia: Clinical practice guidelines from the Society for Vascular Surgery

Huber

Björck

Chandra

et al. 2021

Journal of Vascular Surgery

View full text Add to dashboard Cite

Assessment of recurrent mesenteric ischemia after stenting with a pressure wire

Cited by 3 publications

References 10 publications

Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment

Generation and Characterization of a Multi-Functional Panel of Monoclonal Antibodies for SARS-CoV-2 Research and Treatment

Generation and characterization of a multi-functional panel of monoclonal antibodies for SARS-CoV-2 research and treatment

Chronic mesenteric ischemia: Clinical practice guidelines from the Society for Vascular Surgery

Contact Info

Product

Resources

About